Molnupiravir 400 mg

DRUG2 trials

Sponsors

Ridgeback Biotherapeutics, LP, Oxford University Clinical Research Unit, Vietnam

Conditions

Antiviral DrugsDengueSARS-CoV-2 Infection, COVID-19

Phase 2

Safety, Tolerability and Efficacy of Molnupiravir (EIDD-2801) to Eliminate Infectious Virus Detection in Persons With COVID-19

CompletedNCT04405570

Ridgeback Biotherapeutics, LPSARS-CoV-2 Infection, COVID-19

Start: 2020-06-19End: 2021-02-21Updated: 2022-02-16

Adaptive Dengue Antiviral Platform Trial

Not yet recruitingNCT06551844

Oxford University Clinical Research Unit, VietnamAntiviral Drugs, Dengue

Start: 2025-09-01End: 2030-12-31Target: 500Updated: 2024-08-13

Related Papers

Infectious Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Virus in Symptomatic Coronavirus Disease 2019 (COVID-19) Outpatients: Host, Disease, and Viral Correlates

UNC Libraries2022-11-24

Molnupiravir versus placebo in unvaccinated and vaccinated patients with early SARS-CoV-2 infection in the UK (AGILE CST-2): a randomised, placebo-controlled, double-blind, phase 2 trial

The Lancet Infectious Diseases2022-10-1975 citations

Infectious Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Virus in Symptomatic Coronavirus Disease 2019 (COVID-19) Outpatients: Host, Disease, and Viral Correlates

Clinical Infectious Diseases2021-11-198 citations

Molnupiravir—A Novel Oral Anti-SARS-CoV-2 Agent

Antibiotics2021-10-2385 citations

Therapeutically administered ribonucleoside analogue MK-4482/EIDD-2801 blocks SARS-CoV-2 transmission in ferrets.

2020-12-03308 citations